跳轉至內容
Merck
全部照片(1)

文件

SML0150

Sigma-Aldrich

Tolcapone

≥98% (HPLC)

同義詞:

3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C14H11NO5
CAS號碼:
134308-13-7
分子量：:
273.24
MDL號碼:
MFCD00866569
分類程式碼代碼:
12352200
PubChem物質ID:
329825198
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

yellow

溶解度

DMSO: ≥15 mg/mL

起源

Roche

儲存溫度

2-8°C

SMILES 字串

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

InChI 密鑰

MIQPIUSUKVNLNT-UHFFFAOYSA-N

基因資訊

human ... COMT(1312)

尋找類似的產品？ 前往 產品比較指南

應用

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

生化／生理作用

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

特點和優勢

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Environment
GHS09

訊號詞

Warning

危險聲明

H400

防範說明

P273 - P391 - P501

危險分類

Aquatic Acute 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Daniel D Truong
Clinical interventions in aging, 4, 109-113 (2009-06-09)
Levodopa has been the gold standard therapy for the motor symptoms of Parkinson's disease for more than three decades. Although it remains the most effective treatment, its long-term use is associated with motor fluctuations and dyskinesias that can be disabling
Inès Khsime et al.
International journal of molecular sciences, 24(19) (2023-10-14)
L-DOPA, the precursor of catecholamines, exerts a pro-locomotor action in several vertebrate species, including newborn rats. Here, we tested the hypothesis that decreasing the degradation of monoamines can promote the pro-locomotor action of a low, subthreshold dose of L-DOPA in
Development of an HTRF assay for the detection and characterization of inhibitors of catechol-O-methyltransferase
Kimos M, et al.
Journal of Biomolecular Screening, 21, 490-495 (2016)
Mikael Palner et al.
Nuclear medicine and biology, 37(7), 837-843 (2010-09-28)
R-[(11)C]-SKF 82957 is a high-affinity and potent dopamine D(1) receptor agonist radioligand, which gives rise to a brain-penetrant lipophilic metabolite. In this study, we demonstrate that systemic administration of catechol-O-methyl transferase (COMT) inhibitors blocks this metabolic pathway, facilitating the use
Saviana Di Giovanni et al.
The Journal of biological chemistry, 285(20), 14941-14954 (2010-02-13)
Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of alpha-synuclein (alpha-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務